AI Article Synopsis
- Oncolytic bacteria, particularly attenuated Salmonella typhimurium (VNP20009), show promise as a targeted therapy for tumors, but balancing effectiveness and safety remains a challenge.
- A new delivery system enhances the tumor-targeting capability of VNP20009 by loading it into neutrophils, improving its therapeutic effects in melanoma lung metastasis.
- The addition of a PD1 nanobody to this system boosts immune responses by activating dendritic cell maturation and enhancing the activation of CD4 and CD8 T-cells, leading to improved overall treatment efficacy.
Article Abstract
Oncolytic bacteria are the most promising tumor target vector. Questions also remain regarding finding a balance between the therapeutic efficacy and safety of oncolytic bacteria. The critical measure of how this balance is maintained is the improvement in tumor colonization. Attenuated Salmonella typhimurium (VNP20009) as the only Salmonella strain to be evaluated in a clinical trial is a potential tumor therapeutic bacterium. A delivery system with controlled release of VNP after being loaded into neutrophils, which significantly increases the tumor-targeting of VNP and enhances its therapeutic efficacy in a melanoma lung metastasis model is constructed. To improve the synergistic therapeutic effect, a PD1 nanobody is applied to this system (NE(PD1nb)). NE(PD1nb) activate dendritic cells (DCs) differentiation and stimulate the M1-like differentiation of macrophages, and induce CD4 T-cells maturity and cytotoxic CD8 T-cells activation through DCs tumor antigen presentation.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582430 | PMC |
| http://dx.doi.org/10.1002/advs.202301835 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!